Table 2.
Primary nonresponse | <1 log10 IU/mL decrease in HBV DNA level at 12 weeks of therapy compared with baseline |
Partial virological response | Detectable levels of HBV DNA after 24 weeks (LMV, LdT, ADV) or 48 weeks (ETV, TDF) of therapy in a compliant patient |
Virological breakthrough | Confirmed increase in HBV DNA level of >1 log10 IU/mL compared with the lowest HBV DNA level on therapy (nadir) |